Document is current

Article History

Received: 11 December 2023

Accepted: 14 January 2024

First Online: 9 February 2024

Declarations

:

: Gastón Roustán has been an investigator and/or speaker for Galderma, Pfizer, Abbvie and Sanofi. Marta Loro received speaker honoraria from Sanofi, Novartis, Janssen and Almirall, took part in clinical trials sponsored by Sanofi, Abbvie and Lilly and has received honoraria for her participation in this study. Ángel Rosell received speaker honoraria from Sanofi, Leo Pharma and Abbvie, took part in clinical trials sponsored by Sanofi, Pfizer and Novartis and has received honoraria for his participation in this study. Belén Menchen has participated in conferences, presentations, studies and expert committees organized and funded by Janssen, Leo Pharma, Pfizer, UCB and Novartis. Olga Vicente has received honoraria for her participation in this study and declares no other conflict of interest. Marta Elosua-González has been an investigator and/or speaker for AbbVie, Lilly, Galderma, LEO Pharma, Pfizer, UCB Pharma, and Sanofi Genzyme and has received honoraria for her participation in this study. Juan L. Castaño has received honoraria for his participation in this study and declares no other conflict of interest. Catalina Peña is an employee of Instituto de Experiencia del Paciente. Olga Isidoro is an employee of Laboratorios Galderma.

: This study was performed in accordance with the ethical standards of the Declaration of Helsinki and its amendments. The study was approved by the Ethics Committee of the Puerta de Hierro Majadahonda University (HUPHM) Hospital (Madrid, Spain) with code PI 145/22. All participants provided written informed consent before the interviews and after receiving information about the study.